A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms ...

The findings were reported in Science Translational Medicine. The researchers wanted to measure autoantibody levels in nasal ...

This milestone underscores our unwavering commitment to develop novel, transformational therapies that may help address significant unmet need for patients living with autoantibody-driven diseases." ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

Dr. Ghosn said: “If this nasal autoantibody response turns out to be a common mechanism to protect us against other viral ...

In addition, markers for inflammation and autoantibody testing (like RF and anti-CCP) are negative in fibromyalgia because ...

Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...

Also early in 2024, researchers uncovered a specific autoantibody signature that was evident in some MS patients 5 years ...

Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.

The world will be celebrating diabetes Day on November 14 under the slogan, "Breaking Barriers, Bridging Gaps," to raise awareness and educate people about the nature of the disease and how to deal ...

The Phase 2b LUMUS program for ESK-001 in SLE is designed to evaluate the efficacy, safety and pharmacokinetics of multiple doses of ESK-001 in adult patients with moderately to severely active, ...